211 related articles for article (PubMed ID: 24452282)
61. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.
Dorff TB; Schuckman AK; Schwartz R; Rashad S; Bulbul A; Cai J; Pinski J; Ma Y; Danenberg K; Skinner E; Quinn DI
Clin Genitourin Cancer; 2016 Oct; 14(5):450-456.e1. PubMed ID: 26935231
[TBL] [Abstract][Full Text] [Related]
62. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
[TBL] [Abstract][Full Text] [Related]
63. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
[TBL] [Abstract][Full Text] [Related]
64. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
[TBL] [Abstract][Full Text] [Related]
65. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
66. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract][Full Text] [Related]
67. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
[TBL] [Abstract][Full Text] [Related]
68. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
Friboulet L; Barrios-Gonzales D; Commo F; Olaussen KA; Vagner S; Adam J; Goubar A; Dorvault N; Lazar V; Job B; Besse B; Validire P; Girard P; Lacroix L; Hasmats J; Dufour F; André F; Soria JC
Clin Cancer Res; 2011 Sep; 17(17):5562-72. PubMed ID: 21750204
[TBL] [Abstract][Full Text] [Related]
69. ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples.
Kalogeraki A; Karvela-Kalogeraki I; Tamiolakis D; Petraki P; Saridaki Z; Tzardi M
Rev Port Pneumol; 2014; 20(4):200-7. PubMed ID: 24508180
[TBL] [Abstract][Full Text] [Related]
70. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
Sterlacci W; Fiegl M; Hilbe W; Jamnig H; Oberaigner W; Schmid T; Augustin F; Auberger J; Obermann EC; Tzankov A
J Thorac Oncol; 2010 Sep; 5(9):1325-36. PubMed ID: 20631637
[TBL] [Abstract][Full Text] [Related]
71. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zhao H; Zhang H; Du Y; Gu X
Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
[TBL] [Abstract][Full Text] [Related]
72. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
[TBL] [Abstract][Full Text] [Related]
73. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
Onn A; Correa AM; Gilcrease M; Isobe T; Massarelli E; Bucana CD; O'Reilly MS; Hong WK; Fidler IJ; Putnam JB; Herbst RS
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):136-43. PubMed ID: 14734462
[TBL] [Abstract][Full Text] [Related]
74. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Tsao MS; Sakurada A; Ding K; Aviel-Ronen S; Ludkovski O; Liu N; Le Maître A; Gandara D; Johnson DH; Rigas JR; Seymour L; Shepherd FA
J Thorac Oncol; 2011 Jan; 6(1):139-47. PubMed ID: 21107284
[TBL] [Abstract][Full Text] [Related]
75. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Hirsch FR; Varella-Garcia M; Bunn PA; Di Maria MV; Veve R; Bremmes RM; Barón AE; Zeng C; Franklin WA
J Clin Oncol; 2003 Oct; 21(20):3798-807. PubMed ID: 12953099
[TBL] [Abstract][Full Text] [Related]
76. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
77. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome.
Cubukcu E; Fatih Olmez O; Saraydaroglu O; Akcali U; Kanat O; Kurt E; Evrensel T; Manavoglu O
Clin Transl Oncol; 2011 Nov; 13(11):826-30. PubMed ID: 22082649
[TBL] [Abstract][Full Text] [Related]
78. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
[TBL] [Abstract][Full Text] [Related]
79. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
[TBL] [Abstract][Full Text] [Related]
80. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
